E.L. Kwak

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

John Souglakos, Juliet Philips, R Wang et al. · British Journal of Cancer · 2009 · 320 citations · Full text

Medicine, Genetics, Oncology +17

The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene.

Suzy V. Torti, E.L. Kwak, Shannon C. Miller et al. · Journal of Biological Chemistry · 1988 · 299 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066

E.L. Kwak, D. Ross Camidge, John L. Clark et al. · Journal of Clinical Oncology · 2009 · 205 citations

Medicine, Oncology, Pharmacology +13

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC).

D. Ross Camidge, Yung‐Jue Bang, E.L. Kwak et al. · Journal of Clinical Oncology · 2011 · 135 citations

Medicine, Oncology, Pharmacology +16

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

Y. Bang, E.L. Kwak, Alice T. Shaw et al. · Journal of Clinical Oncology · 2010 · 135 citations

Medicine, Oncology, Pharmacology +14